Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
2020
NCT04587141
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Italian Group for the study of Inflammatory Bowel Disease (IG-IBD)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Iron-Deficiency (Phase 3)

Inflammatory Bowel Diseases (Phase 3)

Intestinal Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3